News · 26 weeks68+7%
2026-04-192026-10-11
Mix4790d
- SEC Filings27(57%)
- Other19(40%)
- Offering1(2%)
Latest news
25 items- SECSEC Form PRE 14A filed by GlucoTrack Inc.PRE 14A - Glucotrack, Inc. (0001506983) (Filer)
- PRQare™ Is Here: Lōkahi Therapeutics™ Launches a Proprietary New Way to Compare Your Care, Beginning with GLP-1 MedicationsNow free on the App Store and Google Play, Qare matches users into cohorts by medication and demographic profile, generating a database of user-reported real-world experience data that Lōkahi believes may become a source of long-term value to patients and manufacturers Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced the public launch of Qare™, a comparative health platform designed to help users compare self-reported treatment experiences across medications within the same therapeutic class. Launching initially in the GLP-1 category, Qare™ enables users to compare their self-reported results, side effects, and out-of-pocket costs against people with
- SECAmendment: SEC Form S-1/A filed by GlucoTrack Inc.S-1/A - Glucotrack, Inc. (0001506983) (Filer)
- SECSEC Form 425 filed by GlucoTrack Inc.425 - Glucotrack, Inc. (0001506983) (Subject)
- SECAmendment: SEC Form 8-K/A filed by GlucoTrack Inc.8-K/A - Glucotrack, Inc. (0001506983) (Filer)
- PRLōkahi Therapeutics™ Expands University of Georgia Collaboration Through First International ai² Pipeline™ Project with Universität PaderbornCross-border initiative expands Lōkahi's university network, increases capacity for additional revenue generating strategic partnerships, and brings together U.S. and German students to identify and evaluate international therapeutic assets with potential for U.S. development and commercialization Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced a new international project with the University of Georgia's Student Industry Fellows Program and Universität Paderborn's garage33 entrepreneurship and innovation center. The Fall 2026 initiative represents the first international expansion of Lōkahi's university-enabled asset evaluation model and builds on its
- PRLōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14Developed Through ai² Accelerator™, Qare™ Is Designed to Enable Users to Compare Their Experiences Against Cohorts of People Like Them, with Additional Drug Classes Expected to Follow Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced Qare™, a comparative health platform designed to evaluate treatment outcomes by comparing experiences across patients using different medications within the same therapeutic class. Introduced on National GLP-1 Day, Qare™ is expected to become publicly available on October 14, 2026. Launching initially in the GLP-1 category, Qare™ is designed to provide a platform for GLP-1 users, regardless of product, to document, organi
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRLōkahi Therapeutics™ Expands ai2 Pipeline™ Program Through Collaboration with Pepperdine E2B™Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that it will partner with Pepperdine E2B™ (Education to Business) to engage students in its ai2 Pipeline™ initiative during the upcoming academic year. The collaboration is intended to provide students with hands-on experience evaluating real-world biopharmaceutical opportunities while supporting Lōkahi's ongoing efforts to identify and assess therapeutic assets through its ai2 platform. The Pepperdine collaboration will begin with a project involving full-time MBA students in a marketing course taught by Professor Kimber Maderazzo at the Pepperdine Graziadio Business School. Through the ai2 Pipeline™ pr
- SECSEC Form 424B5 filed by GlucoTrack Inc.424B5 - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack, Inc. Announces Pricing of $3 Million Public OfferingGlucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company") today announced the pricing of a "best efforts" public offering of 169,388 shares of common stock at a price of $2.04 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase up to 1,350,220 shares of common stock at a price of $2.039 per pre-funded warrant. The Company expects to receive aggregate gross proceeds of approximately $3,100,000, before deducting placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules. The offering is expected to close on or about September 25, 2026, subject to the satisfaction of customary closing conditions.
- PRLōkahi Therapeutics™ Advances its Proprietary ai² PIPELINE (formerly ai² Futures Lab) Process from Internal Asset Engine to Revenue-Generating PlatformInnovate GBM becomes the first external organization to engage the ai² Division on a fee-for-service basis to identify brain tumor therapeutic assets for potential licensing and development Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that Innovate GBM, a 501(c)(3) nonprofit organization dedicated to accelerating the development of new treatments for glioblastoma (GBM) and other brain tumors, has engaged two ai² PIPELINE project teams to identify and evaluate brain tumor therapeutic assets available for licensing and development. Innovate GBM is the first external organization to secure access to the Lōkahi proprietary asset identification pro
- SECGlucoTrack Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- SECSEC Form 425 filed by GlucoTrack Inc.425 - Glucotrack, Inc. (0001506983) (Subject)
- PRLōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development PrioritiesLōkahi Therapeutics™ today issued a strategic corporate update highlighting progress in its LT-100 development program, expansion of its ai² platform, and priorities for advancing and monetizing differentiated therapeutic assets. A Clear View of Who We Are A Message From Our CEO, Erik Emerson Good morning. I'm Erik Emerson, CEO of Lōkahi Therapeutics™ and Glucotrack. As many of you know, we completed our strategic business combination on July 14. Since then, we have continued to work through the post-closing matters contemplated by the transaction, including the steps required for the conversion of the Series A convertible preferred stock, which remains subject to applicable Nasdaq
- SECGlucoTrack Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRLōkahi Therapeutics™ Continues ai² Pipeline™ Division Collaboration with The University of Alabama to Advance Asset Evaluation and Biopharma TalentLōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced that The University of Alabama’s Culverhouse College of Business will continue its participation in the ai² Pipeline division for the upcoming academic year. The renewed collaboration extends a hands-on program in which students evaluate real-world biopharmaceutical business development and asset assessment opportunities. The program also supports Lōkahi’s strategy of identifying and evaluating promising therapeutic assets that may have been overlooked or are no longer being actively developed. During its first year, the ai² Futures Lab™ engaged 64 students and identified more than 45 potential assets, s
- SECSEC Form S-1 filed by GlucoTrack Inc.S-1 - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRGlucotrack Announces $11.5 Million FinancingGlucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company") today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting a 22% original issue discount. The financing is structured as convertible debt with an initial conversion price of $3.12 per share. In connection with the financing, investors will also receive warrants exercisable at $7.50 per share. Dawson James Securities, Inc. acted as Sole Placement Agent for Glucotrack. About Glucotrack, I
- SECGlucoTrack Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities8-K - Glucotrack, Inc. (0001506983) (Filer)
- PRLōkahi Therapeutics™ Expands ai² Into Three Opportunity-Creating Business Divisionsai² Pipeline™, ai² Talent™, and ai² Accelerator™ create potential revenue-generating opportunities while strengthening Lōkahi's therapeutic development platform. Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced the expansion of its ai² platform into three dedicated business divisions: ai² Pipeline™, ai² Talent™, and ai² Accelerator™. The new structure reflects the growth of the Company's actual intelligence-driven platform and is designed to create opportunities for revenue generation while continuing to advance Lōkahi's core pharmaceutical development strategy. Since its launch approximately one year ago, ai² has expanded from a single universi
- PRLōkahi Therapeutics™ Expands ai² Futures Lab™ Asset Origination Network Through Collaboration with San Diego State University Fowler College of BusinessLōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (NASDAQ:GCTK), today announced a collaboration with San Diego State University's (SDSU) Fowler College of Business, expanding the ai² Futures Lab™ and strengthening Lōkahi’s growing network of partner academic institutions. The partnership with SDSU furthers Lōkahi’s work to identify and evaluate promising drug candidates and technologies that may have been overlooked or are no longer being actively developed. The program also supports Lōkahi’s efforts to explore potential new treatments while giving student participants practical experience addressing business challenges in the biopharmaceutical industry. During its first year, the a
GCTK FAQ
5 questionsWhat does GlucoTrack Inc. do?
GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.Where does GCTK stock trade?
GlucoTrack Inc. (GCTK) is listed on NASDAQ.What sector and industry is GCTK in?
GlucoTrack Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What companies are similar to GCTK?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare GCTK side-by-side with any of them on Quantisnow.How can I track GCTK on Quantisnow?
Quantisnow aggregates GlucoTrack Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GCTK to receive live email and push alerts on every new disclosure.